Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2016 | Results of TRIAS 2009 trial of sorafenib with topotecan in ovarian cancer

Jalid Sehouli • 3 Jun 2016
ASCO 2016
Gynecological Cancer Sorafenib Topotecan
TRIAS 2009

Jalid Sehouli, MD, PhD from Charité Comprehensive Cancer Center, Berlin, Germany discusses the Phase II TRIAS 2009 trial of sorafenib with topotecan in patients with platinum-resistant recurrent ovarian cancer (NCT01047891). According to Prof. Sehouli, this combination can increase progression-free survival (PFS) and shows an overall survival (OS) benefit compared to the standard treatment.
Recorded at the 2016 Annual Meeting of the American Society of Clinical Oncology (ASCO), held in Chicago, IL.

More from Jalid Sehouli

1:54
Updates in gynecological cancers at ESMO 2023
Jalid Sehouli • 21 Oct 2023
2:51
Bringing change with TTFields therapy in ovarian cancer
Jalid Sehouli • 21 Oct 2023
2:22
Endometrail cancer patients: global views on genetic counseling and hereditary carcinomas
Jalid Sehouli • 21 Oct 2023
2:42
Breaking bad news in oncology
Jalid Sehouli • 24 Oct 2021

Related Videos

0:39
Early diagnosis of ovarian cancer with Pap smears
Sergio Marchini • 8 Apr 2024
0:46
FRa expression and sequencing ADCs in endometrial cancer
Rebecca Porter • 8 Apr 2024
4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
1:11
Clonal hematopoiesis mutations in ovarian carcinomas
Rebecca Porter • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals